EHA 2023: New Results on Ibrutinib in Combination with Venetoclax in the First-line Treatment of CLL

被引：0

|

作者：

不详

机构：

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：447 / 447

页数：1

相关论文

共 50 条

[31] Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 14 - 15
[32] Is obinutuzumab cost-effective in the first-line treatment of CLL?
Veenstra, David Leroy
Reyes, Carolina M.
Ramsey, Scott David
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[33] The impact of prognostic markers on first-line treatment decisions in CLL
Langerbeins, P.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 4 - +
[34] New Practice Data on Ibrutinib in First-line CLL Therapy Ibrutinib showed significant OS Advantage over FCR in a Real-world Study
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 63 - 63
[35] Combination Therapy as First-Line Treatment for Hypertension
Crawford, Michael H.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2009, 9 (01) : 1 - 6
[36] Combination therapy as first-line treatment for hypertension
Irene Gavras
Talma Rosenthal
Current Hypertension Reports, 2004, 6 : 267 - 272
[37] Combination therapy as first-line treatment for hypertension
Gavras, I
Rosenthal, T
CURRENT HYPERTENSION REPORTS, 2004, 6 (04) : 267 - 271
[38] Combination Therapy as First-Line Treatment for Hypertension
Michael H. Crawford
American Journal of Cardiovascular Drugs, 2009, 9 (1) : 1 - 6
[39] New Options in the First Line Treatment of CLL
Krause, Andreas
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (1-2) : 71 - 71
[40] A confirmed first-line option for CLL
Rebecca Kirk
Nature Reviews Clinical Oncology, 2011, 8 (5) : 253 - 253

← 1 2 3 4 5 →